Identification of Biological Predictive Factors of Clinical Response to Ustekinumab in Patients With Anti-Tumor Necrosis Factor (TNF) Antagonists Refractory Crohn's Disease: Interest of Dosage of C Reactive Protein (CRP), Calprotectin, Ustekinumab Through Levels and Antibodies
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Pharmacodynamics
- Acronyms SAFARI
- 31 Aug 2018 Biomarkers information updated
- 08 Feb 2018 Planned End Date changed from 1 Mar 2018 to 1 Aug 2018.
- 08 Feb 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Aug 2018.